Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
Robbins Y, Greene S, Friedman J, Clavijo PE, Van Waes C, Fabian KP, Padget MR, Abdul Sater H, Lee JH, Soon-Shiong P, Gulley J, Schlom J, Hodge JW, Allen CT.
Robbins Y, et al. Among authors: van waes c.
Elife. 2020 Jul 7;9:e54854. doi: 10.7554/eLife.54854.
Elife. 2020.
PMID: 32633234
Free PMC article.